Biodexa announces successful outcome of a type c meeting with fda regarding the phase 3 program for erapa in fap

March 10, 2025 biodexa announces successful outcome of a type c meeting with fda regarding the phase 3 program for erapa in fap clears the way to finalize phase 3 protocol and recruit sites for u.s. phase 3 substantially funded by $17.0 million cprit grant and $8.5 million company match biodexa pharmaceuticals plc (“biodexa” or the “company”) (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the results of its type c meeting with the u.s. food and drug administration (“fda”) regarding the protocol for the planned registrational phase 3 study of erapa in familial adenomatous polyposis (“fap”). the type c meeting followed a productive end of phase 2 meeting with fda and the publication of phase 2 data of erapa in fap at six months at digestive disease week in may 2024 and 12 months data at insight, barcelona in june 2024.
BDRX Ratings Summary
BDRX Quant Ranking